Technical Analysis for VICL - Vical Incorporated

Grade Last Price % Change Price Change
grade F 0.93 -1.06% -0.01
VICL closed down 1.06 percent on Friday, January 18, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical VICL trend table...

Date Alert Name Type % Chg
Jan 18 Calm After Storm Range Contraction 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 New Downtrend Bearish -1.06%
Jan 17 Calm After Storm Range Contraction -1.06%
Jan 17 Wide Bands Range Expansion -1.06%
Jan 17 Oversold Stochastic Weakness -1.06%
Jan 16 New 52 Week Closing Low Bearish 2.76%

Older signals for VICL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which are under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trial to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy encoding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus, which is marketed for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon in Canada; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. The company was founded in 1987 and is headquartered in San Diego, California.
Is VICL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.82
52 Week Low 0.88
Average Volume 171,532
200-Day Moving Average 1.3385
50-Day Moving Average 1.1785
20-Day Moving Average 1.0588
10-Day Moving Average 1.01
Average True Range 0.0736
ADX 26.17
+DI 14.4483
-DI 31.9031
Chandelier Exit (Long, 3 ATRs ) 1.0292
Chandelier Exit (Short, 3 ATRs ) 1.1008
Upper Bollinger Band 1.2461
Lower Bollinger Band 0.8715
Percent B (%b) 0.16
BandWidth 35.379675
MACD Line -0.0692
MACD Signal Line -0.0535
MACD Histogram -0.0157
Fundamentals Value
Market Cap 10.61 Million
Num Shares 11.4 Million
EPS -1.04
Price-to-Earnings (P/E) Ratio -0.89
Price-to-Sales 2.02
Price-to-Book 0.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.98
Resistance 3 (R3) 0.98 0.97 0.97
Resistance 2 (R2) 0.97 0.96 0.97 0.96
Resistance 1 (R1) 0.95 0.95 0.95 0.95 0.96
Pivot Point 0.94 0.94 0.94 0.94 0.94
Support 1 (S1) 0.92 0.93 0.92 0.92 0.90
Support 2 (S2) 0.91 0.92 0.91 0.90
Support 3 (S3) 0.89 0.91 0.89
Support 4 (S4) 0.89